The Role of Resveratrol Administration in Human Obesity.
Laura Maria MongioìSandro La VigneraRossella CannarellaLaura CiminoMichele CompagnoneRosita Angela CondorelliAldo Eugenio CalogeroPublished in: International journal of molecular sciences (2021)
Obesity is a widespread disease that is associated with numerous and serious comorbidities. These include metabolic syndrome, diabetes mellitus, cardiovascular-cerebrovascular disease, hypertension, obstructive sleep apnea syndrome, cancer, and sexual and hormonal disorders. The treatment of obesity has therefore become a goal of great clinical and social relevance. Among the therapeutic strategies against obesity, resveratrol has aroused great interest. This polyphenol has anticancer and antioxidant properties and cytoprotective and anti-inflammatory effects. Other favorable effects attributed to resveratrol are anti-lipid, anti-aging, anti-bacterial, anti-viral, and neuroprotective actions. Administration of resveratrol appears to improve the metabolic profile in obese and/or insulin-resistant patients. This article aims to review the main results of clinical studies evaluating the effects of administering resveratrol alone in overweight/obese patients.
Keyphrases
- metabolic syndrome
- weight loss
- insulin resistance
- type diabetes
- bariatric surgery
- obese patients
- weight gain
- obstructive sleep apnea
- high fat diet induced
- roux en y gastric bypass
- gastric bypass
- uric acid
- adipose tissue
- endothelial cells
- glycemic control
- blood pressure
- mental health
- newly diagnosed
- polycystic ovary syndrome
- cardiovascular disease
- cardiovascular risk factors
- end stage renal disease
- induced pluripotent stem cells
- healthcare
- smoking cessation
- papillary thyroid
- case report
- combination therapy
- prognostic factors
- fatty acid
- sars cov